Loading organizations...
Loading organizations...
Intellia Therapeutics is a technology company.
Intellia Therapeutics is a clinical-stage genome editing company that develops novel, potentially curative therapeutics leveraging CRISPR technology. The company focuses on making precise changes to DNA to address the root causes of severe genetic diseases, aiming to deliver one-time treatments for patients. This approach represents a fundamental shift in treating disorders currently managed symptomatically.
The company was co-founded in 2014 by Jennifer Doudna, a pioneer in CRISPR-Cas9 gene editing, and Nessan Bermingham, its founding CEO. Their collaboration was built on the insight that the revolutionary potential of CRISPR-Cas9 technology could be harnessed to permanently edit disease-associated genes, offering a pathway to curative medicines for conditions previously considered untreatable. This foundational understanding drove the company’s inception.
Intellia Therapeutics primarily targets individuals afflicted with severe diseases, aiming to provide them with transformative therapeutic options. The company's overarching vision is to revolutionize medicine by developing and commercializing these potentially curative treatments, ultimately striving to significantly improve the lives of patients suffering from debilitating genetic conditions and reshape the future of disease management.
Intellia Therapeutics has raised $85.0M across 2 funding rounds.
Key people at Intellia Therapeutics.
Intellia Therapeutics was founded in 2014 by Jennifer Doudna (Founder) and Erik Sontheimer (Co-Founder) and Derrick Rossi (Founder) and Luciano Marraffini (Founder & Advisor) and Rodolphe Barrangou (Co-Founder).
Intellia Therapeutics has raised $85.0M in total across 2 funding rounds.
Intellia Therapeutics is a clinical-stage biotechnology company pioneering CRISPR/Cas9-based genome editing to develop potentially curative therapies for severe genetic diseases.[1][2][3][4] It targets conditions like hereditary angioedema (HAE) with NTLA-2002 and transthyretin (ATTR) amyloidosis with nexiguran ziclumeran (nex-z), addressing unmet needs by editing disease-causing genes directly in the body rather than managing symptoms.[1][4] The company serves patients with life-threatening disorders, leveraging partnerships like Regeneron for in vivo delivery, with significant R&D investment—$481.7 million in fiscal 2024—fueling a pipeline of transformative programs.[1]
Intellia Therapeutics was founded in 2014 by pioneers in CRISPR/Cas9 technology, driven by the belief that this system could permanently edit disease-associated genes with a single treatment.[2][3] The idea emerged from the rapid advancement of CRISPR as a precise, programmable tool for gene editing, offering hope for curing chronic conditions where prior options failed.[3] Early traction came from assembling deep scientific expertise, a leading IP portfolio, and strategic collaborations, positioning Intellia to translate CRISPR from lab discovery to clinic—evidenced by advancing late-stage programs like nex-z, with positive Phase 1 data in ATTR amyloidosis patients.[1][4]
Intellia rides the gene editing revolution, harnessing CRISPR's simplicity, specificity, and programmability to unlock cures for genetic disorders amid rising demand for precision medicine.[2][3] Timing aligns with maturing CRISPR tech, regulatory progress (e.g., first approvals), and market forces like aging populations driving ATTR and HAE needs.[1][4] It influences the ecosystem by validating in vivo editing, inspiring competitors, and expanding CRISPR beyond ex vivo cell therapies into mainstream oncology and rare diseases.[2]
Intellia is poised to deliver first-in-class approvals for nex-z and NTLA-2002, potentially establishing CRISPR as a blockbuster platform with durable revenue from one-time dosing.[1][4] Trends like AI-optimized editing, expanded delivery tech, and combo therapies will accelerate its pipeline into new indications, while partnerships mitigate cash burn. Its influence could grow by democratizing curative gene edits, transforming biotech from symptom relief to root-cause cures—cementing its role as a genome editing trailblazer.[2][3]
Intellia Therapeutics was founded in 2014 by Jennifer Doudna (Founder) and Erik Sontheimer (Co-Founder) and Derrick Rossi (Founder) and Luciano Marraffini (Founder & Advisor) and Rodolphe Barrangou (Co-Founder).
Intellia Therapeutics has raised $85.0M in total across 2 funding rounds.
Intellia Therapeutics's investors include OrbiMed, Aisling Capital, Atlas Venture, General Atlantic, The Column Group, EcoR1 Capital, Fidelity Management & Research Company, Foresite Capital, Janus Henderson Investors, Novartis, Sectoral Asset Management.
Key people at Intellia Therapeutics.
Intellia Therapeutics has raised $85.0M across 2 funding rounds. Most recently, it raised $70.0M Series B in August 2015.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2022 | Kyverna Therapeutics | $85.0M Series B | Northpond Ventures | Access Biotechnology, venBio, Westlake Village BioPartners, Sean Harper, Argentum Capital Partners, CAM Capital, Mark Genovese, HealthCor, Hudson Bay Capital, Insight Partners, jVen Capital, LYFE Capital, Niu (Chris) Liu, Fred Cohen |
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2015 | $70.0M Series B | OrbiMed | Aisling Capital, Atlas Venture, General Atlantic, The Column Group, EcoR1 Capital, Fidelity Management & Research Company, Foresite Capital, Janus Henderson Investors, Novartis, Sectoral Asset Management |
| Nov 1, 2014 | $15.0M Series A | Atlas Venture |